ACP-103, a 5-HT2A receptor inverse agonist.
ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the effects of the drug on PD symptoms and dyskinesias.
Roberts
Claire
C
Psychiatry Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline plc, Harlow, UK. Claire.Roberts@gsk.com
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D006801:Humans; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity
D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D017366:Serotonin Receptor Agonists; D014508:Urea; C510793:pimavanserin